Is Mounjaro better than Ozempic?

Q: How common are Mounjaro side effects?

Mounjaro (tirzepatide) shares a similar side effect profile with Ozempic. Nausea is the most common (12-18%), followed by diarrhea (12-17%), decreased appetite (5-11%), vomiting (5-9%), and constipation (6%). These GI effects are most pronounced during dose escalation and generally improve over time

Q: What happens if you stop taking Mounjaro?

Like other GLP-1/GIP receptor agonists, stopping Mounjaro typically leads to weight regain. Clinical trial extension data shows that patients who discontinued tirzepatide regained a substantial portion of lost weight within 12 months, as the appetite-suppressing and gastric-slowing effects disappear

Q: Is Ozempic safe long term?

Ozempic (semaglutide) has been studied in trials lasting up to 2 years, with no new safety signals emerging beyond those seen in shorter studies. The most common long-term concerns are gastrointestinal side effects like nausea (which typically improve after the first few months), a small increased r

Direct Answer

In head-to-head trial data, tirzepatide (Mounjaro) produced greater weight loss than semaglutide (Ozempic): approximately 20-22% vs. 14-15% body weight reduction. Mounjaro works on two receptors (GLP-1 and GIP) compared to Ozempic's one (GLP-1 only). Both are weekly injections at similar price points ($1,000+/month without insurance). Side effect profiles are comparable, with GI symptoms being the most common for both. However, Ozempic has longer cardiovascular outcomes data (SUSTAIN-6 showed reduced heart events). Both require ongoing use to maintain benefits. The "better" choice depends on your specific goals and medical history.

Based on published clinical trial data and FDA prescribing information. This is not medical advice — always consult your healthcare provider.

Supporting Evidence

Side Effects

Nausea31–36%

Diarrhea20–23%

Vomiting13–16%

Constipation17–19%

Decreased appetite40%+

Serious (rare)

Pancreatitis (<1%) — discontinue and do not restart if confirmed
Gallbladder disease / gallstones (rapid weight loss increases risk)
Kidney injury (from dehydration, not direct nephrotoxicity)

Clinical Trials

Expected HbA1c reduction: −1.87% to −2.46% from baseline (SURPASS-1, 5–15mg). SURPASS-2: tirzepatide superior to semaglutide 1mg for HbA1c. SURMOUNT-1: −22.5% body weight at 72 weeks (15mg). SURMOUNT-4: full weight regain within 1 year of stopping — documented in the withdrawal arm.

SURPASS-1 (Lilly)SURPASS-2 (Lilly)SURPASS-3 (Lilly)

Cost & Pricing

List Price

$1,069

With Insurance

$25–200

Funding & Conflicts

All SURPASS and SURMOUNT trials were designed, funded, and controlled by Eli Lilly. Lilly reported $5.8B in tirzepatide revenue in 2024 alone — its fastest product ramp in history. Lead investigators across all trials received advisory fees, speaker payments, and research grants from Lilly. The company employs the investigators, owns the patient-level data, and controls publication timing.

Conflicts of Interest

Eli Lilly's DTC marketing budget for tirzepatide exceeds $1B annually. Key obesity researchers who co-authored trial publications receive six-figure consulting fees from Lilly and other GLP-1 manufacturers. The Obesity Society and American Diabetes Association both receive substantial pharmaceutical funding. SURMOUNT-4's withdrawal arm — showing full weight regain within 1 year of stopping — received minimal media attention compared to the initial weight-loss results.

Funding transparency: All SURPASS and SURMOUNT trials were designed, funded, and controlled by Eli Lilly. Lilly reported $5.8B in tirzepatide revenue in 2024 alone — its fastest product ramp in history. Lead investigators … See full funding details

Read the complete Mounjaro® / Zepbound® guide

Side effect rates, clinical trial data, funding transparency, drug interactions, tapering protocols, and lifestyle alternatives — all in one place.

View Mounjaro® / Zepbound®